Abstract
1. In dogs, atabrine medication with 33 or 66 per cent of the acute m.l.d. daily for 14 and 4 consecutive days respectively resulted in impairment of hepatic function as measured by the bromsulphalein and bilirubin tests.
2. In contrast daily medication with 17 per cent of the m.l.d. for 6 weeks revealed no significant reduction in liver function in 3 of the 4 dogs studied.
3. Chronic dosages of atabrine ranging from 17 to 66 per cent of the m.l.d. administered daily for a period of 42 days gave no evidence of renal damage in 11 of 12 dogs studied.
Footnotes
- Received June 25, 1938.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.